Determination of chlorzoxazone in rat plasma by LC-ESI-MS/MS and its application to a pharmacokinetic study

Analytical Letters

Volumn 43, Issue 15, 2010, Pages 2424-2431

  Wang, Xianqin ^a   Hu, Lufeng ^b   Tong, Shuhua ^a   Zheng, Yangming ^c   Ye, Faqing ^a   Lin, Dan ^a   Lin, Guanyang ^b   Zhang, Xiuhua ^b   Wu, Haiya ^c  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^c THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Chlorzoxazone; LC ESI MS=MS; Pharmacokinetics; Rat plasma

Indexed keywords

RATTUS;

EID: 78049332542     PISSN: 00032719     EISSN: 1532236X     Source Type: Journal    
DOI: 10.1080/00032711003717430     Document Type: Article

References (21)

1. Ahn, C. Y., S. K. Bae, Y. S. Jung, I. Lee, Y. C. Kim, M. G. Lee, and W. G. Shin. 2008. Pharmacokinetic parameters of chlorzoxazone and its main metabolite, 6-hydroxychlorzoxazone, after intravenous and oral administration of chlorzoxazone to liver cirrhotic rats with diabetes mellitus. Drug. Metab. Dispos. 36: 1233-1241.
2. Axelsson, H., C. Granhall, E. Floby, Y. Jaksch, M. Svedling, and A. K. Sohlenius-Sternbeck. 2003. Rates of metabolism of chlorzoxazone, dextromethorphan,7-ethoxycoumarin, imipramine, quinidine, testosterone and verapamil by fresh and cryopreserved rat liver slices, and some comparisons with microsomes. Toxicol. in. Vitro. 17: 481-488.
3. Baek, H. W., S. K. Bae, M. G. Lee, and Y. T. Sohn. 2006. Pharmacokinetics of chlorzoxazone in rats with diabetes: Induction of CYP2E1 on 6-hydroxychlorzoxazone formation. J. Pharm. Sci. 95: 2452-2462.
4. Blakey, G. E., J. A. Lockton, J. Perrett, P. Norwood, M. Russell, Z. Aherne, and J. Plume. 2004. Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1. Br. J. Clin. Pharmacol. 57: 162-169.
5. Cox, S. K., T. Hamner, and J. Bartges. 2003. Determination of 6-hydroxychlorzoxazone and chlorzoxazone in porcine microsome samples. J. Chromatogr. B 784: 111-116.
6. Dinc, E., A. Ozdemir, H. Aksoy, and D. Baleanu. 2006. Chemometric approach to simultaneous chromatographic determination of paracetamol and chlorzoxazone in tablets and spiked human plasma. J. Liq. Chromatogr. R. T. 29: 1803-1822.
7. Du, Y., F. Wang, R. H. Zhu, F. L. Su, J. Song, and H. D. Li. 2007. Determination of chlorzoxazone and its metabolite in human plasma by HPLC-MS. Chin. Pharm. J. 42: 1011-1014.
8. Eap, C. B., C. Schnyder, and L. Savary. 1998. Determination of chlorzoxazone and 6-hydroxychlorzoxazone in plasma by gas chromatography-mass spectrometry. J. Chromatogr. B 705: 139-144.
9. Frye, R. F., and D. D. Stiff. 1996. Determination of chlorzoxazone and 6-hydroxychlorzoxazone in human plasma and urine by high-performance liquid chromatography. J. Chromatogr. B 686: 291-296.
10. Kim, R. B., D. O'Shea, and G. R. Wilkinson. 1995. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin. Pharmacol. Ther. 57: 645-655.
11. Leclercq, I., Y. Horsmans, and J. P. Desager. 1998. Estimation of chlorzoxazone hydroxylase activity in liver microsomes and of the plasma pharmacokinetics of chlorzoxazone by the same high-performance liquid chromatographic method. J. Chromatogr. A 828: 291-296.
12. Lucas, D., F. Berthou, C. Girre, F. Poitrenaud, and J. F. Ménez. 1993. High performance liquid chromatographic determination of chlorzoxazone and 6-hydroxychlorzoxazone in serum: A tool for indirect evaluation of cytochrome P450 2E1 activity in humans. J. Chromatogr. 622: 79-86.
13. Lucas, D., C. Menez, C. Girre, F. Berthou, P. Bodenez, I. Joannet, E. Hispard, L. G. Bardou, and J. F. Menet. 1995. Cytochrome P450 2E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects. Pharmacogentics. 5: 298-304.
14. Muzeeb, S., M. K. Pasha, S. J. S. Basha, R. Mullangi, and N. R. Srinivas. 2005. Effect of 1-aminobenzotriazole on the in vitro metabolism and single-dose pharmacokinetics of chlorzoxazone, a selective CYP2E1 substrate in Wistar rats. Xenobiotica. 35: 825-838.
15. Peter, R., R. Bocker, P. H. Beaune, M. Iwasaki, F. P. Guengerich, and C. S. Yang. 1990. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem. Res. Toxicol. 3: 566-573.
16. Petsalo, A., M. Turpeinen, O. Pelkonen, and A. Tolonen. 2008. Analysis of nine drugs and their cytochrome P450-specific probe metabolites from urine by liquid chromatographytandem mass spectrometry utilizing sub 2 microm particle size column. J. Chromatogr. A 1215: 107-115.
17. Rajnarayana, K., S. R. Mada, J. Vidyasagar, P. Kishore, and D. R. Krishna. 2002. Validated HPLC method for determination of chlorzoxazone in human serum and its application in a clinical pharmacokinetic study. Pharmazi. 57: 811-813.
18. Scott, R. J., J. Palmer, I. A. S. Lewis, and S. Pleasance. 1999. Determination of a "GW cocktail" of cytochrome P450 probe substrates and their metabolites in plasma and urine using automated solid phase extraction and fast gradient liquid chromatography tandem mass spectrometry. Rapid. Commun. Mass. Sp. 13: 2305-2319.
19. Tanaka, E. 1998. Simultaneous determination of chlorzoxazone, indicator of CYP2E1, and its metabolite in human serum using a new reversed-phase chromatographic column of 2-microm porous microspherical silica-gel. J. Pharm. Biomed. Anal. 16: 899-904.
20. Tortorici, M. A., P. M. Kochanek, R. R. Bies, and S. M. Poloyac. 2006. Therapeutic hypothermia-induced pharmacokinetic alterations on CYP2E1 chlorzoxazone-mediated metabolism in a cardiac arrest rat model. Crit. Care. Med. 34: 785-791.
21. Vesell, E. S., T. D. Seaton, and Y. I. A-Rahim. 1995. Studies on interindividual variations of CYP2E1 using chlorzoxazone as an in vivo probe. Pharmacogentics. 5: 53-57.